DOAC
E861729
DOAC (direct oral anticoagulant) is a class of blood-thinning medications that directly inhibit specific clotting factors to prevent and treat thromboembolic events.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant drug
ⓘ
class of medication ⓘ |
| abbreviationOf | direct oral anticoagulant ⓘ |
| alternativeTo | warfarin NERFINISHED ⓘ |
| benefitComparedToWarfarin |
fewer drug interactions (agent-dependent)
ⓘ
fewer food interactions ⓘ fixed dosing ⓘ no routine INR monitoring ⓘ |
| clinicalGuidelineUse | recommended first-line for non-valvular atrial fibrillation in many guidelines ⓘ |
| comparedTo | vitamin K antagonist ⓘ |
| contraindicatedIn |
mechanical heart valves
ⓘ
severe renal impairment ⓘ |
| drugInteractionWith |
strong CYP3A4 inhibitors
ⓘ
strong P-glycoprotein inhibitors ⓘ |
| elimination | renal excretion (varies by agent) ⓘ |
| fullName | direct oral anticoagulant ⓘ |
| hasAdverseEffect |
bleeding
ⓘ
gastrointestinal bleeding ⓘ intracranial hemorrhage ⓘ |
| hasMechanismOfAction | direct inhibition of specific coagulation factors ⓘ |
| hasPharmacologicalEffect | anticoagulation ⓘ |
| hasReversalAgent |
andexanet alfa
NERFINISHED
ⓘ
idarucizumab ⓘ |
| hasReversalStrategy | prothrombin complex concentrate GENERATED ⓘ |
| hasSubclass |
direct thrombin inhibitor
ⓘ
factor Xa inhibitor ⓘ |
| includesDrug |
apixaban
NERFINISHED
ⓘ
betrixaban NERFINISHED ⓘ dabigatran NERFINISHED ⓘ edoxaban NERFINISHED ⓘ rivaroxaban NERFINISHED ⓘ |
| metabolism | hepatic metabolism (varies by agent) ⓘ |
| monitoringRequirement | no routine coagulation monitoring required in most patients ⓘ |
| onsetOfAction | rapid ⓘ |
| requiresDoseAdjustmentIn |
hepatic impairment
ⓘ
renal impairment ⓘ |
| riskComparedToWarfarin |
higher cost
ⓘ
limited use in severe renal dysfunction ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
coagulation factor IIa
ⓘ
coagulation factor Xa ⓘ |
| usedFor |
prevention of recurrent deep vein thrombosis
ⓘ
prevention of recurrent pulmonary embolism ⓘ prevention of stroke in non-valvular atrial fibrillation ⓘ prevention of thromboembolic events ⓘ treatment of deep vein thrombosis ⓘ treatment of pulmonary embolism ⓘ treatment of thromboembolic events ⓘ venous thromboembolism prophylaxis after orthopedic surgery ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.